Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T18551 Target Info
Target Name CD80-PD-L1 interaction (CD80/PD-L1 PPI)
Synonyms T-lymphocyte activation antigen CD80/Programmed cell death 1 ligand 1 PPI
Target Type Patented-recorded Target
Gene Name CD80-CD274
UniProt ID
CD80_HUMAN - PD1L1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2018044963
Title Biaryl Compounds Useful As Immunomodulators.
Abstract The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0D3RS Drug Info N.A. Click to Show More [1]
2 D0N5NV Drug Info N.A. [1]
Patent ID WO2018026971
Title Symmetric or Semi-Symmetric Compounds Useful As Immunomodulators.
Abstract A compound having Formula I:(I), or a pharmaceutical acceptable salt thereof. A is a bivalent arene or a bivalent heteroarene; Ring B and Ring B' are independently a 6-membered aromatic hydrocarbon ring, a 6-membered heterocyclic ring, a 8- to 10-membered aromatic hydrocarbon ring, or a 8- to 10-membered heterocyclic ring; Y and Y' are independently, null (direct bond), -CHR1-, -CH2-CH2-, -NR1-, -0-, -OCH2-, -CH2O-, -SCH2-, -CH2S-, -SOCH2-, -CH2SO-, or -SO2CH2-, and R1 is H, C1-6 alkyl, or C3-6 cycloalkyl.
Applicant(s) Arising International, Inc
Representative Drug(s) D04PCT Drug Info N.A. Click to Show More [1]
2 D0M6WW Drug Info N.A. [1]
Patent ID WO2017176608
Title Macrocyclic Inhibitors of The Pd-1/Pd-L1 and Cd80/Pd-L1 Protein/Protein Interactions.
Abstract The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-Ll and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. wherein: A is selected from a bond.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D03BCV Drug Info N.A. Click to Show More [1]
2 D0N4TZ Drug Info N.A. [1]
3 D0NI2B Drug Info N.A. [1]
4 D0QF4W Drug Info N.A. [1]
5 D0R7JW Drug Info N.A. [1]
Patent ID WO2016126646
Title Immunomodulators.
Abstract The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D07ZQS Drug Info N.A. [1]
Patent ID WO2016100608
Title Immunomodulators.
Abstract The present disclosure provides novel macrocyclic peptides of formula (I) which inhibit the PD-l/PD-Ll and PD-L1/CD80 protein/ protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D03BCV Drug Info N.A. Click to Show More [1]
2 D0N4TZ Drug Info N.A. [1]
3 D0NI2B Drug Info N.A. [1]
4 D0QF4W Drug Info N.A. [1]
5 D0R7JW Drug Info N.A. [1]
Patent ID WO2016077518
Title Macrocyclic Peptides Useful As Immunomodulators.
Abstract The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D03BCV Drug Info N.A. Click to Show More [1]
2 D0N4TZ Drug Info N.A. [1]
3 D0NI2B Drug Info N.A. [1]
4 D0QF4W Drug Info N.A. [1]
5 D0R7JW Drug Info N.A. [1]
Patent ID WO2016039749
Title Macrocyclic Inhibitors of The Pd-1/Pd-L1 and Cd80 (B7-1)/Pd-Li Protein/Protein Interactions.
Abstract The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D03BCV Drug Info N.A. Click to Show More [1]
2 D0N4TZ Drug Info N.A. [1]
3 D0NI2B Drug Info N.A. [1]
4 D0QF4W Drug Info N.A. [1]
5 D0R7JW Drug Info N.A. [1]
United States Patent and Trademark Office (USPTO)
Patent ID US20170252432
Title Immunomodulators.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D03BCV Drug Info N.A. Click to Show More [1]
2 D0N4TZ Drug Info N.A. [1]
3 D0NI2B Drug Info N.A. [1]
4 D0QF4W Drug Info N.A. [1]
5 D0R7JW Drug Info N.A. [1]
Patent ID US20160340391
Title Macrocyclic Inhibitors of The Pd-1/Pd-L1 and Cd80(B7-1)/Pd-L1 Protein/Protein Interactions.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D06VTI Drug Info N.A. Click to Show More [1]
2 D08EHL Drug Info N.A. [1]
3 D0J4UO Drug Info N.A. [1]
Patent ID US20140294898
Title Macrocyclic Inhibitors of The Pd-1/Pd-L1 and Cd80(B7-1)/Pd-L1 Protein/Protein Interactions.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D06VTI Drug Info N.A. Click to Show More [1]
2 D08EHL Drug Info N.A. [1]
3 D0J4UO Drug Info N.A. [1]
References  Top
REF 1 A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.